Literature DB >> 2108579

Serum myoinositol concentrations in premature infants fed human milk, formula for infants, and parenteral nutrition.

G R Pereira1, L Baker, J Egler, L Corcoran, R Chiavacci.   

Abstract

Myoinositol concentration was studied in serum of 65 neonates and their mothers at the time of birth, in samples of various types of feedings for infants, and in serial serum samples of 15 premature infants receiving human milk, formulas for infants, or parenteral nutrition over a 3-wk period. At birth the serum concentration of myoinositol was greater in neonates than in their mothers (108 +/- 10 vs 52 +/- 6 mumol/L, respectively, means +/- SEM, p less than 0.01). In feedings for infants, the concentrations of myoinositol were significantly greater in human milk than in formulas or parenteral nutrition solutions (1840 +/- 451 vs 420 +/- 110 vs 100 +/- 8 mumol/L, respectively, p less than 0.001). Over a 3-wk period the serum concentration of myoinositol increased in infants receiving human milk but not in those receiving formulas or parenteral nutrition. Serum concentrations of myoinositol in neonates are greater than in adults and are directly influenced by myoinositol intake.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2108579     DOI: 10.1093/ajcn/51.4.589

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  9 in total

Review 1.  Current perspectives on the drug treatment of neonatal respiratory distress syndrome.

Authors:  D G Sweet; H L Halliday
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

Review 2.  Donor Human Milk Update: Evidence, Mechanisms, and Priorities for Research and Practice.

Authors:  Paula Meier; Aloka Patel; Anita Esquerra-Zwiers
Journal:  J Pediatr       Date:  2016-10-20       Impact factor: 4.406

3.  Influence of own mother's milk on bronchopulmonary dysplasia and costs.

Authors:  Aloka L Patel; Tricia J Johnson; Beverley Robin; Harold R Bigger; Ashley Buchanan; Elizabeth Christian; Vikram Nandhan; Anita Shroff; Michael Schoeny; Janet L Engstrom; Paula P Meier
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2016-11-02       Impact factor: 5.747

4.  Inositol and mannose utilization rates in term and late-preterm infants exceed nutritional intakes.

Authors:  Laura D Brown; Alex Cheung; Jeri E F Harwood; Frederick C Battaglia
Journal:  J Nutr       Date:  2009-06-03       Impact factor: 4.798

5.  Time series community genomics analysis reveals rapid shifts in bacterial species, strains, and phage during infant gut colonization.

Authors:  Itai Sharon; Michael J Morowitz; Brian C Thomas; Elizabeth K Costello; David A Relman; Jillian F Banfield
Journal:  Genome Res       Date:  2012-08-30       Impact factor: 9.043

6.  Inositol in preterm infants at risk for or having respiratory distress syndrome.

Authors:  Alexandra Howlett; Arne Ohlsson; Nishad Plakkal
Journal:  Cochrane Database Syst Rev       Date:  2019-07-08

7.  Genome resolved analysis of a premature infant gut microbial community reveals a Varibaculum cambriense genome and a shift towards fermentation-based metabolism during the third week of life.

Authors:  Christopher T Brown; Itai Sharon; Brian C Thomas; Cindy J Castelle; Michael J Morowitz; Jillian F Banfield
Journal:  Microbiome       Date:  2013-12-17       Impact factor: 14.650

8.  Blood myo-inositol concentrations in preterm and term infants.

Authors:  Luc P Brion; Dale L Phelps; Robert M Ward; Tracy L Nolen; N Mikko K Hallman; Abhik Das; Daniel J Zaccaro; M Bethany Ball; Kristi L Watterberg; Ivan D Frantz; C Michael Cotten; Brenda B Poindexter; William Oh; Ralph A Lugo; Krisa P Van Meurs; T Michael O'Shea; Kristin M Zaterka-Baxter; Rosemary D Higgins
Journal:  J Perinatol       Date:  2020-09-15       Impact factor: 2.521

Review 9.  New Frontiers for the Use of IP6 and Inositol Combination in Treating Diabetes Mellitus: A Review.

Authors:  Felix O Omoruyi; Dewayne Stennett; Shadae Foster; Lowell Dilworth
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.